Provided by Tiger Fintech (Singapore) Pte. Ltd.

Geron

1.35
+0.08006.30%
Post-market: 1.380.0300+2.22%19:58 EDT
Volume:15.60M
Turnover:21.19M
Market Cap:859.82M
PE:-5.00
High:1.43
Open:1.27
Low:1.27
Close:1.27
Loading ...

Company Profile

Company Name:
Geron
Exchange:
NASDAQ
Establishment Date:
1990
Employees:
229
Office Location:
919 East Hillsdale Boulevard,Suite 250,Foster City,California,United States
Zip Code:
94404
Fax:
- -
Introduction:
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.

Directors

Name
Position
John A. Scarlett
President, Chief Executive Officer and Chairman of the Board
Dawn C. Bir
Director
Elizabeth G. O'Farrell
Director
Karin Eastham
Director
Robert J. Spiegel
Director
Susan M. Molineaux
Director
V. Bryan Lawlis
Director

Shareholders

Name
Position
John A. Scarlett
President, Chief Executive Officer and Chairman of the Board
Andrew J. Grethlein
Executive Vice President, Chief Operating Officer
Olivia K. Bloom
Executive Vice President, Finance, Chief Financial Officer
Aleksandra Rizo
Executive Vice President, Chief Medical Officer
Anil Kapur
Executive Vice President, Corporate Strategy and Chief Commercial
Melissa A. Kelly Behrs
Executive Vice President, Chief Business Officer
Stephen N. Rosenfield
Executive Vice President, Chief Legal Officer and Corporate Secretary